Role of DcR3 in T Cell Activation in SLE and RA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00275899|
Recruitment Status : Unknown
Verified December 2005 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : January 12, 2006
Last Update Posted : January 12, 2006
|Condition or disease|
|SLE Rheumatoid Arthritis|
Specific Aim 1. Study DcR3-induced T cell activation in SLE and RA. A. Patients and controls Patients with SLE and RA in Department of Internal Medicine, National Taiwan University Hospital will be studied. All patient meet the criteria of the American College of Rheumatologists for diagnosis of SLE and RA. As controls, 20 healthy age- and gender-matched volunteers will be used. All the studies including samples involving human is in accordance with institutional guidelines.
B. Detection of serum DcR3 protein in SLE and RA patients C. T cell proliferation assay
Specific Aim 2. Study effects of DcR3 on activation-induced cell death (AICD) in SLE and RA In order to understand whether DcR3 could reduce the AICD in activated T cells in SLE and RA patients, the T cells from these patients will be assayed their AICD in the presence and absence of soluble DcR3-Fc.
Specific Aim 3. To investigate the association of clinical manifestation of SLE and RA with genetic polymorphism on DcR3 genes.
A. The gene sequencing and single nucleotide polymorphism (SNP) analysis of DcR3 genes.
B. The association of clinical manifestation of SLE and RA with genetic polymorphism on DcR3 genes.
|Study Type :||Observational|
|Enrollment :||450 participants|
|Observational Model:||Case Control|
|Official Title:||Role of DcR3 in T Cell Activation in SLE and RA|
|Study Start Date :||January 2006|
|Study Completion Date :||December 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00275899
|Contact: Ping-Ning Hsu, PhD||886-2-23123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Contact: Ping-Ning Hsu, MD, PhD +886-223123456 ext 8635 firstname.lastname@example.org|
|Principal Investigator: Ping-Ning Hsu, MD, PhD|
|Principal Investigator:||Ping-Ning Hsu, MD, PhD||Department of Immunology|